HGH Fragment 176-191 5mg 

EACH VIAL CONTAINS 5MG OF HGH Fragment

Supplied for Research Purposes Only

This information and product is provided for research purposes only. We do not provide any advice on the usage of these products as UK Law prevents this. Customers should check the legality of this product in their own country prior to purchase.

Benefits and uses:

Growth hormone like fat loss without the adverse effects on insulin sensitivity.

Dose:

Week 1: 250mcg x2 per week 

Week 2: 500mcg x2 per week 

Week 3: 750mcg x2 per week  

Week 4: 1000mcg x2 per week 

Research on Human Growth Hormone Fragment 176-191 1. HGH Fragment 176-191 and Blood Sugar

The hypoglycemic effects of human growth hormone (hGH), also known as reducing blood sugar, have been shown to be predominantly caused by the c-terminal end of the protein through research conducted on animals. After testing at least six distinct fragments produced from this region of hGH, researchers determined that fragment 176-191 is the synthetic derivative of hGH that is most successful at reducing levels of blood sugar. This impact is a secondary one, and it is caused by a persistent increase in the levels of plasma insulin [1]. The use of fragment 176-191 as a therapy for both prediabetes and type 2 diabetes is something that has garnered some attention recently.

Fragment 176-191, Fat Burning And Weight Loss

Due to the findings of tests conducted on mice, fragment 176-191, also known as the "lipolytic fragment," was found to have significant fat-burning and weight-loss properties. As a result, the fragment gained the nickname. It is believed that this effect is caused by an increase in the synthesis of beta-3 adrenergic receptors (also known as ADRB3 or 3-AR) [2]. A direct increase in the rate at which fat is burned in adipose tissue by agonist activity at ADRB3, which is also responsible for thermogenesis in skeletal muscle, is known to be the case [3]. The genetic modification of mice so that they produce no ADRB3 renders them incapable of responding to the lipolytic effects of either hGH or fragment 176-191 [2].

According to studies, the increased fat burning that is associated with fragment 176-191 has a direct correlation with increased energy expenditure and, as a result, weight loss. This leads to an almost fifty percent reduction in the amount of weight gain that occurs in obese animals over the course of three weeks [4]. It is interesting to note that the effects on weight loss were only observed in obese mice, whereas lean mice maintained normal body weight, on average, even when they were exposed to fragment 176-191[2]. These findings suggest that there are other regulatory pathways for lipolysis that, when body weight is at or near optimal, can override the action of ADRB3, opening up possibilities for further investigation into energy homeostasis.

Fragment 176-191 and the regeneration of cartilage

Despite the fact that the lipolytic characteristics of fragment 176-191 are the primary reason for its attention, the peptide is currently being studied for a variety of additional potentially beneficial effects. It is important to note that research published in Korea in 2015 found that fragment 176-191 has the potential to boost the effects of hyaluronic acid injections on cartilage regeneration. This research was published in the journal Cell Reports. According to research conducted on rabbits, weekly injections of fragment 176-191 boost laboratory measures of cartilage formation. Furthermore, co-administration of the peptide with hyaluronic acid (HA) causes results that are even more significant. In a similar vein, the research concluded that the use of fragment 176-191 either by alone or in conjunction with HA is effective in lessening the disability caused by osteoarthritis. There is reason to believe that this will eventually result in the development of more advanced treatments for osteoarthritis, some of which may even make surgery superfluous in certain circumstances [7].

Studies on the Subject of Safety, Fragments 176-191

The usage of human growth hormone (hGH) or one of its derivatives for the purpose of weight control has been met with some degree of scepticism. The fact that research on hGH have revealed that long-term exogenous injection, whilst increasing lean body mass and lowering adipose tissue, can also induce the following side effects:

elevated levels of insulin resistance, diabetes, acromegaly, cancer, hypertension, often known as high blood pressure, as well as edoema (swelling).

In 2013, a study that was published in the Journal of Endocrinology and Metabolism reviewed six different studies of fragment 176-191 in order to determine the frequency of adverse effects associated with the peptide as well as the relevance of those effects. In order to maintain the highest possible standards of evidence, the study only considered previous research that had been conducted in accordance with the randomised, double-blind, placebo-controlled model of a phase IIb clinical trial. When compared to placebo, it was discovered that intravenous and oral administration of Fragment 176-191 did not lead to any changes in the following characteristics:

glucose levels, glucose tolerance, insulin sensitivity, IGF-1 levels, or rates of unpleasant events such as headaches [4, 5]. [Citation needed]

According to the findings of this meta-analysis, fragment 176-191 may provide many of the advantages that are associated with human growth hormone (hGH), but without the adverse effects that are typically associated with it. These findings not only bolster the case for seeking regulatory permission for the use of fragment 176-191 in therapeutic settings, but they also shed light on the factors that regulate human growth, fat deposition, and energy homeostasis. These findings make it abundantly evident that it is possible to target fat loss without compromising energy balance in other nutrition pathways. This opens the door for a more in-depth investigation of human energy control and approaches for influencing it.

It is important to note that although human growth hormone (hGH) has anabolic effects on muscle, fragment 176-191 was purposefully chosen because of its capacity to completely avoid these effects. It is imperative that this be done in order to guarantee that the peptide will have the desired lipolytic effects without causing acromegaly or any of the other diseases that are commonly connected with the administration of hGH. According to research conducted on mice, segment 176-191 does not stimulate an increase in cell proliferation [6].

Reference:

[1] F. M. Ng and J. Bornstein, “Hyperglycemic action of synthetic C-terminal fragments of human growth hormone,” Am. J. Physiol., vol. 234, no. 5, pp. E521-526, May 1978. [PubMed]

[2] M. Heffernan et al., “The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice andβ 3-AR Knock-Out Mice,” Endocrinology, vol. 142, no. 12, pp. 5182–5189, Dec. 2001. [PubMed]

[3] R. Ferrer-Lorente, C. Cabot, J.-A. Fernández-López, and M. Alemany, “Combined effects of oleoyl-estrone and a beta3-adrenergic agonist (CL316,243) on lipid stores of diet-induced overweight male Wistar rats,” Life Sci., vol. 77, no. 16, pp. 2051–2058, Sep. 2005. [PubMed]

[4] F. M. Ng, J. Sun, L. Sharma, R. Libinaka, W. J. Jiang, and R. Gianello, “Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone,” Horm. Res., vol. 53, no. 6, pp. 274–278, 2000. [PubMed]

[5] H. Stier, E. Vos, and D. Kenley, “Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans,” J. Endocrinol. Metab., vol. 3, no. 1–2, pp. 7-15–15, Apr. 2013. [PubMed]

[6] M. A. Heffernan et al., “Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment,” Int. J. Obes. Relat. Metab. Disord. J. Int. Assoc. Study Obes., vol. 25, no. 10, pp. 1442–1449, Oct. 2001. [PubMed]

[7] D. R. Kwon and G. Y. Park, “Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model,” Ann. Clin. Lab. Sci., vol. 45, no. 4, pp. 426–432, Jul. 2015. [PubMed]